GFPT1 and breast carcinoma: To assess the clinical significance of GFPT1 expression, we applied the pRRophetic algorithm and package to analyze the half-maximal inhibitory concentration (IC50) values of eight commonly used chemotherapeutic agents in breast cancer treatment, including Cisplatin, Doxorubicin, Docetaxel, Gemcitabine, Imatinib, Paclitaxel, Vinblastine, and Vinorelbine, across GFPT1-High and GFPT1-Low groups in BRCA.